Literature DB >> 22643116

Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck.

T S Clauditz1, C-J Wang, A Gontarewicz, M Blessmann, P Tennstedt, K Borgmann, S Tribius, G Sauter, C Dalchow, R Knecht, A Münscher, W Wilczak.   

Abstract

BACKGROUND: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) was found overexpressed in various cancer types suggesting its possible role in carcinogenesis. Analysis of IMP3 expression in head and neck squamous cell carcinomas (HNSCC) is rare so that we evaluated it using tissue microarray method.
METHOD: Immunohistochemical analysis of IMP3 was performed on samples from over 400 patients. The expression was measured semiquantitative, subsequently divided into four categories (negative, weak, medium, or strong) and correlated with several available clinicopathologic parameters.
RESULTS: For HNSCC, positive IMP3 expression was observed in patients with all tumor stages (pT1-4) and nodal stages (pN0-3), showing also significant statistical correlation (P=0.023 and P=0.0013, respectively). No further correlations were found. Separate analysis according to tumor localization (oral cavity, oropharyngeal, and laryngeal) showed a significant correlation of positive IMP3 expression and overall survival (P=0.038) only in patients with tumors of the oral cavity. Multivariate analysis showed IMP3 as an independent predictive marker for oral squamous cell carcinomas (OSCC).
CONCLUSION: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression might be used as an independent prognostic factor in the subgroup of OSCC.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22643116     DOI: 10.1111/j.1600-0714.2012.01178.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  21 in total

1.  IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status.

Authors:  Emanuel Adelino M Damasceno; Fabiana Pirani Carneiro; Albino Verçosa de Magalhães; Marcos de Vasconcelos Carneiro; Gustavo Henrique Soares Takano; Leonora Maciel de Sousa Vianna; Heinrich Bender Kohnert Seidler; Tercia Maria Mendes Lousa de Castro; Maria Imaculada Muniz-Junqueira; Rivadávio Fernandes Batista Amorim; Vânia Maria Moraes Ferreira; Andrea Barreto Motoyama
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-17       Impact factor: 4.553

2.  IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis.

Authors:  Marc-Oliver Riener; Josef Hoegel; Heinrich Iro; Arndt Hartmann; Abbas Agaimy
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

3.  Role of panendoscopy in identifying and managing risk of head and neck squamous cell carcinoma in routine follow-up: a retrospective clinical evaluation.

Authors:  Adrian Münscher; Susanne Sehner; Jegane Taleh; Silke Tribius; Nicolaus Möckelmann; Arne Böttcher; Amit Gulati; Carsten Dalchow; Till Clauditz; Rainald Knecht
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-07       Impact factor: 2.503

4.  Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.

Authors:  Nazia Syed; Sandip Chavan; Nandini A Sahasrabuddhe; Santosh Renuse; Gajanan Sathe; Vishalakshi Nanjappa; Aneesha Radhakrishnan; Remya Raja; Sneha M Pinto; Anand Srinivasan; T S Keshava Prasad; Kotteazeth Srikumar; Harsha Gowda; Vani Santosh; David Sidransky; Joseph A Califano; Akhilesh Pandey; Aditi Chatterjee
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

5.  IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.

Authors:  S Soddu; E Di Felice; S Cabras; M E Castellanos; L Atzori; G Faa; L Pilloni
Journal:  Eur J Histochem       Date:  2013-02-14       Impact factor: 3.188

6.  An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.

Authors:  Masatoshi Hirayama; Yusuke Tomita; Akira Yuno; Hirotake Tsukamoto; Satoru Senju; Yuya Imamura; Mohammad Abu Sayem; Atsushi Irie; Yoshihiro Yoshitake; Daiki Fukuma; Masanori Shinohara; Akinobu Hamada; Hirofumi Jono; Eiji Yuba; Kenji Kono; Koji Yoshida; Takuya Tsunoda; Hideki Nakayama; Yasuharu Nishimura
Journal:  Oncoimmunology       Date:  2016-01-04       Impact factor: 8.110

7.  Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.

Authors:  Akiko Kanzaki; Mitsuhiro Kudo; Shin-Ichi Ansai; Wei-Xia Peng; Kousuke Ishino; Tetsushi Yamamoto; Ryuichi Wada; Takenori Fujii; Kiyoshi Teduka; Kiyoko Kawahara; Yoko Kawamoto; Taeko Kitamura; Seiji Kawana; Hidehisa Saeki; Zenya Naito
Journal:  Int J Oncol       Date:  2016-01-05       Impact factor: 5.650

8.  IGF2BP3 as a potential tissue marker for the diagnosis of esophageal high-grade intraepithelial neoplasia.

Authors:  Jingjing Zhang; Qing Ji; Chunhua Jiao; Lihua Ren; Ye Zhao; Yanfang Chen; Ruihua Shi; Yadong Feng
Journal:  Onco Targets Ther       Date:  2017-08-01       Impact factor: 4.147

Review 9.  The biological function of IGF2BPs and their role in tumorigenesis.

Authors:  Qiu-Ying Du; Zhi-Man Zhu; Dong-Sheng Pei
Journal:  Invest New Drugs       Date:  2021-07-12       Impact factor: 3.850

10.  A six-mRNA signature model for the prognosis of head and neck squamous cell carcinoma.

Authors:  Wenna Guo; Xijia Chen; Liucun Zhu; Qiang Wang
Journal:  Oncotarget       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.